Copyright
©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 6-12
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.6
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.6
Table 1 Metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer in the SPARTAN, PROSPER, and ARAMIS randomized controlled trials
| Objective: MFS | n | HR for MFS | 95%CI; P value |
| Apalutamide vs placebo (SPARTAN) | 1207 | 0.28 | 0.23-0.35; < 0.0001 |
| Enzalutamide vs placebo (PROSPER) | 1401 | 0.29 | 0.24-0.35; < 0.0001 |
| Darolutamide vs placebo (ARAMIS) | 1509 | 0.41 | 0.34-0.50; < 0.001 |
- Citation: Henriquez I, Spratt D, Gómez-Iturriaga A, Abuchaibe O, Couñago F. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. World J Clin Oncol 2021; 12(1): 6-12
- URL: https://www.wjgnet.com/2218-4333/full/v12/i1/6.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i1.6